|
UA59384C2
(uk)
*
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
|
AU735137B2
(en)
*
|
1997-02-21 |
2001-07-05 |
Bayer Intellectual Property Gmbh |
Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders
|
|
JP4253126B2
(ja)
*
|
1998-01-29 |
2009-04-08 |
アムジェン インコーポレイテッド |
Ｐｐａｒ−ガンマ調節剤
|
|
DE19837627A1
(de)
|
1998-08-19 |
2000-02-24 |
Bayer Ag |
Neue Aminosäureester von Arylsulfonamiden und Analoga
|
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
|
DE10015866A1
(de)
*
|
2000-03-30 |
2001-10-11 |
Bayer Ag |
Aryl- und Heteroarylsulfonate
|
|
US20090124690A1
(en)
*
|
2000-04-03 |
2009-05-14 |
Alberte Randall S |
Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
|
|
AU6118001A
(en)
|
2000-05-03 |
2001-11-12 |
Tularik Inc |
Combination therapeutic compositions and methods of use
|
|
US20030171399A1
(en)
*
|
2000-06-28 |
2003-09-11 |
Tularik Inc. |
Quinolinyl and benzothiazolyl modulators
|
|
DE10047486A1
(de)
*
|
2000-09-26 |
2002-04-11 |
Bayer Ag |
Phenoxyphenyl Alkansulfonate
|
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
|
UA75093C2
(en)
|
2000-10-06 |
2006-03-15 |
Dimensional Pharm Inc |
Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
|
|
GB0028702D0
(en)
|
2000-11-24 |
2001-01-10 |
Novartis Ag |
Organic compounds
|
|
AU2006200813A1
(en)
*
|
2000-11-24 |
2006-03-16 |
Novartis Ag |
Naphthalene derivatives
|
|
US6708906B2
(en)
*
|
2000-12-29 |
2004-03-23 |
Siemens Automotive Corporation |
Modular fuel injector having a surface treatment on an impact surface of an electromagnetic actuator and having an integral filter and dynamic adjustment assembly
|
|
US7507767B2
(en)
|
2001-02-08 |
2009-03-24 |
Schering Corporation |
Cannabinoid receptor ligands
|
|
AU2002319627A1
(en)
|
2001-07-20 |
2003-03-03 |
Merck And Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
|
US20040171613A1
(en)
*
|
2001-12-27 |
2004-09-02 |
Japan Tobacco Inc. |
Therapeutic agent for non-immediate type allergic diseases
|
|
WO2003061699A1
(en)
*
|
2001-12-27 |
2003-07-31 |
Japan Tobacco, Inc. |
Remedies for allergic diseases
|
|
ATE447971T1
(de)
*
|
2002-02-19 |
2009-11-15 |
Shionogi & Co |
Antipruriginosa
|
|
WO2003075917A1
(en)
|
2002-03-08 |
2003-09-18 |
Signal Pharmaceuticals, Inc. |
Combination therapy for treating, preventing or managing proliferative disorders and cancers
|
|
JP3813152B2
(ja)
|
2002-03-12 |
2006-08-23 |
メルク エンド カムパニー インコーポレーテッド |
置換アミド類
|
|
AU2003215024B2
(en)
|
2002-03-26 |
2008-02-21 |
Merck Sharp & Dohme Corp. |
Spirocyclic amides as cannabinoid receptor modulators
|
|
EP1492784A4
(en)
|
2002-03-28 |
2006-03-29 |
Merck & Co Inc |
SUBSTITUTED 2,3-DIPHENYLPYRIDINES
|
|
DE10215942A1
(de)
*
|
2002-04-11 |
2003-10-23 |
Bayer Ag |
Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
|
|
AU2003223510B2
(en)
|
2002-04-12 |
2008-05-08 |
Merck Sharp & Dohme Corp. |
Bicyclic amides
|
|
US7176322B2
(en)
|
2002-05-23 |
2007-02-13 |
Amgen Inc. |
Calcium receptor modulating agents
|
|
US6908935B2
(en)
|
2002-05-23 |
2005-06-21 |
Amgen Inc. |
Calcium receptor modulating agents
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
US7094789B2
(en)
*
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
|
EP1549621A1
(en)
*
|
2002-08-08 |
2005-07-06 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
|
JP2006510597A
(ja)
|
2002-09-27 |
2006-03-30 |
メルク エンド カムパニー インコーポレーテッド |
置換ピリミジン類
|
|
US7378525B2
(en)
*
|
2002-12-23 |
2008-05-27 |
Millennium Pharmaceuticals, Inc. |
CCR8 inhibitors
|
|
TW200510311A
(en)
*
|
2002-12-23 |
2005-03-16 |
Millennium Pharm Inc |
CCr8 inhibitors
|
|
US7491827B2
(en)
*
|
2002-12-23 |
2009-02-17 |
Millennium Pharmaceuticals, Inc. |
Aryl sulfonamides useful as inhibitors of chemokine receptor activity
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2005037286A1
(en)
*
|
2003-03-25 |
2005-04-28 |
Vasopharm Biotech Gmbh |
Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
|
|
ATE532509T1
(de)
*
|
2003-09-11 |
2011-11-15 |
Tibotec Pharm Ltd |
Mittel zur hemmung des eintritts des hiv-virus
|
|
EP1663113A4
(en)
*
|
2003-09-18 |
2007-06-13 |
Merck & Co Inc |
SUBSTITUTED SULFONAMIDE
|
|
ATE547404T1
(de)
|
2003-09-22 |
2012-03-15 |
Msd Kk |
Piperidinderivate
|
|
US7223761B2
(en)
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
|
US20050250820A1
(en)
*
|
2004-03-08 |
2005-11-10 |
Amgen Inc. |
Therapeutic modulation of PPARgamma activity
|
|
EP1734963A4
(en)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
|
|
CA2581454A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyrimidine compounds, process for their preparation and compositions containing them
|
|
CN101094689B
(zh)
|
2004-11-01 |
2013-06-12 |
安米林药品有限责任公司 |
治疗肥胖以及肥胖相关疾病和病症的方法
|
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
|
WO2006051704A1
(ja)
*
|
2004-11-15 |
2006-05-18 |
Taisho Pharmaceutical Co., Ltd. |
イミン化合物
|
|
WO2007022123A2
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
ES2351613T3
(es)
*
|
2005-03-03 |
2011-02-08 |
Santen Pharmaceutical Co., Ltd. |
Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
|
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
|
BRPI0610580B8
(pt)
|
2005-05-30 |
2021-05-25 |
Banyu Pharma Co Ltd |
composto derivado de piperidina
|
|
CA2613678A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
JPWO2007018248A1
(ja)
|
2005-08-10 |
2009-02-19 |
萬有製薬株式会社 |
ピリドン化合物
|
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
WO2007024004A1
(ja)
|
2005-08-24 |
2007-03-01 |
Banyu Pharmaceutical Co., Ltd. |
フェニルピリドン誘導体
|
|
WO2007029847A1
(ja)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
二環性芳香族置換ピリドン誘導体
|
|
EP1940842B1
(en)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
EP1944301A4
(en)
|
2005-10-27 |
2012-01-04 |
Msd Kk |
NEW BENZOXATHIIN DERIVATIVES
|
|
ES2381205T3
(es)
|
2005-11-10 |
2012-05-24 |
Msd K.K. |
Derivado espiro aza-sustituido
|
|
CA2657247A1
(en)
*
|
2006-07-28 |
2008-01-31 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
US8173629B2
(en)
|
2006-09-22 |
2012-05-08 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
US7928123B2
(en)
*
|
2006-09-25 |
2011-04-19 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the CB2 receptor
|
|
US20090247560A1
(en)
|
2006-09-28 |
2009-10-01 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
WO2008098025A1
(en)
*
|
2007-02-08 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Arylsulfonamide compounds which modulate the cb2 receptor
|
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Ｍｓｄ株式会社 |
インドールジオン誘導体
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
|
CA2704684A1
(en)
*
|
2007-11-07 |
2009-05-14 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
UA97707C2
(ru)
*
|
2007-11-14 |
2012-03-12 |
Амилин Фармасьютикалз, Инк. |
Способы лечения ожирения и заболеваний, расстройств, связанных с ожирением
|
|
EP2264026A4
(en)
|
2008-03-06 |
2012-03-28 |
Msd Kk |
ALKYLAMINOPYRIDINDERIVATE
|
|
WO2009119726A1
(ja)
|
2008-03-28 |
2009-10-01 |
萬有製薬株式会社 |
メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
|
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
JPWO2009154132A1
(ja)
|
2008-06-19 |
2011-12-01 |
Ｍｓｄ株式会社 |
スピロジアミン−ジアリールケトオキシム誘導体
|
|
US8178568B2
(en)
*
|
2008-07-10 |
2012-05-15 |
Boehringer Ingelheim International Gmbh |
Sulfone compounds which modulate the CB2 receptor
|
|
EP2319841A1
(en)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
|
CA2737639A1
(en)
|
2008-09-25 |
2010-04-01 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the cb2 receptor
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
MX2011004551A
(es)
|
2008-10-30 |
2011-05-25 |
Merck Sharp & Dohme |
Antagonistas del receptor de orexina de isonicotinamida.
|
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
|
EP2379547A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
|
JP2012513464A
(ja)
|
2008-12-23 |
2012-06-14 |
ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク |
ホスホジエステラーゼ阻害剤及びその使用
|
|
US8299103B2
(en)
*
|
2009-06-15 |
2012-10-30 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the CB2 receptor
|
|
JP5756800B2
(ja)
|
2009-06-16 |
2015-07-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
|
|
WO2011037795A1
(en)
*
|
2009-09-22 |
2011-03-31 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the cb2 receptor
|
|
JP5788404B2
(ja)
|
2009-12-11 |
2015-09-30 |
アウトイフオンイ トヘラペウトイクス リミテッド |
イミダゾリジンジオン誘導体
|
|
WO2011088015A1
(en)
|
2010-01-15 |
2011-07-21 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
|
US8329735B2
(en)
|
2010-03-05 |
2012-12-11 |
Boehringer Ingelheim International Gmbh |
Tetrazole compounds which selectively modulate the CB2 receptor
|
|
WO2012012307A1
(en)
|
2010-07-22 |
2012-01-26 |
Boehringer Ingelheim International Gmbh |
Sulfonyl compounds which modulate the cb2 rece
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
SG192941A1
(en)
|
2011-02-25 |
2013-09-30 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
RU2015106909A
(ru)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
Антидиабетические трициклические соединения
|
|
KR20150118158A
(ko)
|
2013-02-22 |
2015-10-21 |
머크 샤프 앤드 돔 코포레이션 |
항당뇨병 비시클릭 화합물
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2015054662A1
(en)
|
2013-10-10 |
2015-04-16 |
Eastern Virginia Medical School |
4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
|
|
KR102431436B1
(ko)
|
2014-08-29 |
2022-08-10 |
테스 파마 에스.알.엘. |
α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
|
|
US9585867B2
(en)
|
2015-08-06 |
2017-03-07 |
Charles Everett Ankner |
Cannabinod formulation for the sedation of a human or animal
|
|
WO2018069532A1
(en)
|
2016-10-14 |
2018-04-19 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
AR117122A1
(es)
|
2018-11-20 |
2021-07-14 |
Tes Pharma S R L |
INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
|
|
WO2020167701A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
Pyrrolidine orexin receptor agonists
|
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
BR112023002957A2
(pt)
|
2020-08-18 |
2023-04-04 |
Merck Sharp & Dohme Llc |
Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
|